ENLV

1.05010.26%
GH

Gili Hart

Independent Director

Dr. Gili Hart, Ph.D, has been Chief Executive Officer at Splisense Ltd since 2020. She served as General Manager at OPKO Biologic’s since 2014. From 2017 and until 2020, Dr. Hart served as the Chief Executive Officer of Mitoconix since 2017 until 2019 and from 2014 and until 2017 she served as the Chief Executive Officer of OPKO Biologics. Dr. Hart has extensive experience in managing critical global programs ranging from preclinical work through Phase 3 clinical trials. Dr. Hart has broad experience in global regulatory strategic planning and interactions and partnering deals with large-pharma, public company road shows and financing. Dr. Hart served as Vice President of Pre-clinical and Clinical Pharmacology in PROLOR Biotech from 2011 to 2014 and served as its Senior Director. During the period from 2005 to 2007, Dr. Hart was a Research Fellow in the Immunology Department at the Weizmann Institute of Science in collaboration with Faculty of Immunobiology, Yale University’s School of Medicine. Dr. Hart has published numerous papers and patents and in her scientific work, she focused on autoimmunity diseases as well as on B and T cells migration that can directly affect inflammation and immune conditions. She had been an Independent Director of CollPlant Biotechnologies Ltd. (formerly, CollPlant Holdings Ltd.) since July 7, 2017 until July 05, 2023. She has been an Independent Director of Enlivex Therapeutics Ltd. since 2014. Dr. Hart holds a B.Sc degree in Biological engineering and an M.Sc degree from the Weizmann Institute of Science and M.Sc. degree in Biotechnology Engineering, summa cum laude, from the Technion – Israel Institute of Technology as well as a Ph.D. from the Weizmann Institute of Science.

Positions